Al Nahdi Medical Company SJSC

The company's capital structure is characterized by a debt-to-equity ratio of 0.65, indicating a moderate level of leverage. Its liquidity position is assessed as medium, with a current ratio of 1.54, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company has no cash and equivalents, and its net cash is negative after subtracting total debt, which could pose liquidity challenges. In terms of profitability, the company's return on equity (ROE) is 30.28%, and its return on assets (ROA) is 12.42%, both of which are strong indicators of efficient use of equity and assets to generate profit. The operating margin, calculated as operating income divided by revenue, is 9.07%, which is a key metric for assessing the company's operational efficiency. Geographically, the company's revenue is concentrated in its domestic market, with no disclosed international segments. The company's exposure to different business segments is not specified, but its primary revenue stream is from the retail of pharmaceuticals and healthcare products. The company's growth trajectory is not explicitly detailed in the provided data, but its operating cash flow of 1.13 billion SAR and free cash flow of 479.83 million SAR suggest a positive cash flow generation capability. The company's capital expenditure of -417.62 million SAR indicates a reduction in capital spending, which could be a strategic move to preserve cash. The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints. The company's dilution potential is low, and no adjustments have been applied to its valuation metrics. Recent events and filings have not been detailed in the provided data, but the company's financial performance and analyst estimates suggest a stable outlook. The mean price target of 126.56 SAR and the median price target of 127.00 SAR indicate a positive sentiment among analysts.